Want to see HK:6929 full AI Analyst Report?
6929 Stock Chart & Stats
HK$4.44
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$4.44
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$3.45 - HK$5.10
Previous CloseN/A
Volume48.00K
Average Volume (3M)98.92K
Market Cap
HK$3.16B
Enterprise ValueHK$1.72K
Total Cash (Recent Filing)HK$199.23M
Total Debt (Recent Filing)HK$6.77M
Price to Earnings (P/E)9.1
Beta0.57
Next Earnings
Mar 11, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield7.01%
Share Statistics
EPS (TTM)0.05
Shares Outstanding827,968,300
10 Day Avg. Volume65,800
30 Day Avg. Volume98,916
Financial Highlights & Ratios
PEG Ratio1.57
Price to Book (P/B)0.93
Price to Sales (P/S)2.13
P/FCF Ratio333.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$5.30Price Target Upside19.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.06
Revenue Forecast (FY)HK$207.00M
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthSustained revenue expansion indicates continued demand for the company’s interventional cardiology and endovascular products. Growth across several years provides a durable base for operating leverage, product adoption and broader international commercialization.
Strong Gross MarginsConsistently high gross margins support the economics of the device portfolio and provide resilience against manufacturing, distribution and research costs. This profitability cushion can help fund innovation and market expansion over the medium term.
Conservative Balance SheetVery low leverage materially reduces financial risk and interest burdens, preserving flexibility to invest in product development, manufacturing capacity and international distribution. The large equity base also strengthens resilience through changing industry conditions.
Bears Say
Weak Cash ConversionWeak conversion of accounting earnings into operating cash may indicate working-capital or reinvestment pressure. If sustained, it could constrain internally funded growth and reduce the company’s ability to convert strong reported margins into financial flexibility.
Very Low Free Cash FlowPersistently subdued free cash flow reduces the cash available for product development, acquisitions, dividends or balance-sheet strengthening. The recent decline suggests that investment needs or working-capital requirements are absorbing a larger share of operating resources.
Margin CompressionMargin deterioration despite continued sales growth indicates that incremental revenue is currently less profitable than before. If this persists, it could limit earnings growth, weaken returns on capital and reduce the benefits of the company’s strong gross-margin profile.
OrbusNeich Medical Group Holdings Limited News
6929 FAQ
What was OrbusNeich Medical Group Holdings Limited’s price range in the past 12 months?
OrbusNeich Medical Group Holdings Limited lowest stock price was HK$3.45 and its highest was HK$5.10 in the past 12 months.
What is OrbusNeich Medical Group Holdings Limited’s market cap?
OrbusNeich Medical Group Holdings Limited’s market cap is HK$3.16B.
When is OrbusNeich Medical Group Holdings Limited’s upcoming earnings report date?
OrbusNeich Medical Group Holdings Limited’s upcoming earnings report date is Mar 11, 2027 which is in 183 days.
How were OrbusNeich Medical Group Holdings Limited’s earnings last quarter?
OrbusNeich Medical Group Holdings Limited released its earnings results on Aug 13, 2026. The company reported HK$0.204 earnings per share for the quarter.
Is OrbusNeich Medical Group Holdings Limited overvalued?
According to Wall Street analysts OrbusNeich Medical Group Holdings Limited’s price is currently Undervalued.
Does OrbusNeich Medical Group Holdings Limited pay dividends?
OrbusNeich Medical Group Holdings Limited pays a Quarterly dividend of HK$0.08 which represents an annual dividend yield of 7.01%. See more information on OrbusNeich Medical Group Holdings Limited dividends here
What is OrbusNeich Medical Group Holdings Limited’s EPS estimate?
OrbusNeich Medical Group Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OrbusNeich Medical Group Holdings Limited have?
OrbusNeich Medical Group Holdings Limited has 827,968,300 shares outstanding.
What happened to OrbusNeich Medical Group Holdings Limited’s price movement after its last earnings report?
OrbusNeich Medical Group Holdings Limited reported an EPS of HK$0.204 in its last earnings report. Following the earnings report the stock price went up 0.395%.
Which hedge fund is a major shareholder of OrbusNeich Medical Group Holdings Limited?
Currently, no hedge funds are holding shares in HK:6929
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OrbusNeich Medical Group Holdings Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.50%
12-Months-Change
Fundamentals
Return on Equity
7.01%
Trailing 12-Months
Asset Growth
3.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
OrbusNeich Medical Group Holdings Limited
OrbusNeich Medical Group Holdings Limited functions as an investment holding entity, specializing in the development, distribution, sales, and marketing of medical instruments tailored for treating coronary and peripheral vascular ailments. The company boasts a significant international presence, serving markets across Japan, Europe, the Middle East, Africa, the Asia Pacific region, the People's Republic of China, and the United States. Its product offerings encompass a range of essential devices, including semi-compliant and scoring balloons used for initial vessel preparation, coronary stents for implantation, non-compliant balloons designed for post-dilatation, and a variety of specialized catheters. This extensive portfolio of products addresses critical steps within percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Founded in 2001, the company is headquartered in Shatin, Hong Kong, and operates as a subsidiary of Harmony Tree Limited.
6929 Stock 12 Month Forecast
Average Price Target
HK$5.30
▲(19.37% Upside)
Technical Analysis
Shandong Weigao Group Medical Polymer Co
―
PW Medtech Group Ltd.
―
Modern Dental Group Limited
―
Shanghai Kindly Medical Instruments Co., Ltd. Class H
―
Angelalign Technology Inc.
―